Baihua Pharmaceutical announced that Cathay Pacific Haitong Securities issued continuing supervision opinions on the acquisition of the company by Jinhua Juxin in the second quarter of 2026. On June 9, 2026, the company's 795.251 million shares transferred by Jinhua Juxin completed transfer registration. The controlling shareholder of the company was changed to Jinhua Juxin, and the actual controller was changed to the Jinhua State-owned Assets Administration Commission. During the supervision period, the acquirer did not violate relevant commitments, did not adjust the company's main business, did not carry out major asset disposal or restructuring, did not propose adjustments to directors, supervisors, articles of association, employee employment and dividend policies, and did not harm the interests of listed companies.

Baihua Pharmaceutical announced that Cathay Pacific Haitong Securities issued continuing supervision opinions on the acquisition of the company by Jinhua Juxin in the second quarter of 2026. On June 9, 2026, the company's 795.251 million shares transferred by Jinhua Juxin completed transfer registration. The controlling shareholder of the company was changed to Jinhua Juxin, and the actual controller was changed to the Jinhua State-owned Assets Administration Commission. During the supervision period, the acquirer did not violate relevant commitments, did not adjust the company's main business, did not carry out major asset disposal or restructuring, did not propose adjustments to directors, supervisors, articles of association, employee employment and dividend policies, and did not harm the interests of listed companies.